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Abstract 
Aims Accelerometers are becoming increasingly commonplace for assessing physical activity; however, their use in patients 
with cardiovascular diseases is relatively substandard. We aimed to systematically review the methods used for collecting and 
processing accelerometer data in cardiology, using the example of heart failure, and to provide practical recommendations on 
how to improve objective physical activity assessment in patients with cardiovascular diseases by using accelerometers. 
Methods and results Four electronic databases were searched up to September 2019 for observational, interventional, and 
validation studies using accelerometers to assess physical activity in patients with heart failure. Study and population charac-
teristics, details of accelerometry data collection and processing, and description of physical activity metrics were extracted 
from the eligible studies and synthesized. To assess the quality and completeness of accelerometer reporting, the studies were 
scored using 12 items on data collection and processing, such as the placement of accelerometer, days of data collected, and 
criteria for non-wear of the accelerometer. In 60 eligible studies with 3500 patients (of those, 536 were heart failure with pre-
served ejection fraction patients), a wide variety of accelerometer brands (n = 27) and models (n = 46) were used, with 
Actigraph being the most frequent (n = 12), followed by Fitbit (n = 5). The accelerometer was usually worn on the hip 
(n = 32), and the most prevalent wear period was 7 days (n = 22). The median wear time required for a valid day was 
600 min, and between two and five valid days was required for a patient to be included in the analysis. The most common 
measures of physical activity were steps (n = 20), activity counts (n = 15), and time spent in moderate-to-vigorous physical 
activity (n = 14). Only three studies validated accelerometers in a heart failure population, showing that their accuracy dete-
riorates at slower speeds. Studies failed to report between one and six (median 4) of the 12 scored items, with non-wear time 
criteria and valid day definition being the most underreported items. 
Conclusions The use of accelerometers in cardiology lacks consistency and reporting on data collection, and processing 
methods need to be improved. Furthermore, calculating metrics based on raw acceleration and machine learning techniques 
is lacking, opening the opportunity for future exploration. Therefore, we encourage researchers and clinicians to improve the 
quality and transparency of data collection and processing by following our proposed practical recommendations for using ac-
celerometers in patients with cardiovascular diseases, which are outlined in the article. 
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Introduction atherosclerosis, hypertension, and chronic heart failure 
(HF),1–3 it is important that PA and sedentary behaviour can 
Because physical activity (PA) plays a crucial role in be properly assessed by researchers and clinicians alike. 
preventing and managing cardiovascular diseases such as Traditionally, PA has been assessed using questionnaires, 
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but recent evidence shows that questionnaires have numer-
ous limitations, including recall bias, missing data, and less 
precision.4 Therefore, interest in objectively assessing PA 
has proliferated, with accelerometers representing the most 
popular tool used in contemporary research. Despite this, 
several systematic reviews have recently reported that the 
quality of accelerometry-based PA assessment is relatively 
poor in studies in patients with cardiovascular diseases.5–7 
As poor or inaccurate assessment of PA using accelerometry 
can deleteriously impact the advancement of PA research in 
cardiology and impede its translation into clinical practice, it 
is crucial that we understand how accelerometers have been 
used in cardiology to date. 
To address this issue, we chose HF as an example of a car-
diovascular disease, because of its increasing prevalence and 
economic burden, and because the benefits of PA for patients 
with HF are well established.2,6,8 We conducted a systematic 
review of studies using accelerometers in HF patients with 
the aims (i) to explore the methods used for collecting and 
processing accelerometry data, (ii) to evaluate 
accelerometry-based metrics used for the assessment of PA, 
(iii) to examine the quality of reporting on data collection 
and processing, (iv) to review the validity of accelerometers 
in this population, and (v) to provide practical recommenda-
tions for researchers and clinicians on how to objectively as-
sess PA and sedentary behaviour in patients with 
cardiovascular diseases using accelerometers. 
Methods 
The present review was conducted in accordance with the 
PRISMA (Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses) statement, and the review protocol has 
been registered in the international prospective register of 
systematic reviews (PROSPERO: CRD42019125427). 
Search strategy 
The following electronic bibliographic databases were 
searched: PubMed, SPORTDiscus (via EBSCO), Scopus, and 
IEEE Xplore Digital Library. The search strategy combined 
terms for HF (e.g. ‘heart failure’ and ‘HFrEF’) AND terms to 
identify articles dealing with accelerometers (e.g. ‘accelerom-
eter’ and ‘inertial sensor’). The search terms for individual da-
tabases are available as Data S1. The search was limited to 
papers published in English-language academic journals. 
Studies published from the inception of the databases up 
to September 2019 were sought. Additionally, the reference 
lists of recently published reviews5–7 were hand searched 
for further studies. Titles and abstracts of the retrieved stud-
ies were screened to identify studies that potentially meet 
the eligibility criteria. The full texts of these potentially 
eligible studies were assessed for eligibility by two review au-
thors (T. V. and C. C.); any disagreement was resolved 
through discussion with a third reviewer (M. B.). 
Eligibility criteria 
The eligibility criteria fall into four areas: study types, patient 
population, devices, and PA metrics. 
(1) Study types. A wide range of study types was eligible for 
the review, including observational and interventional 
studies, as well as validation and calibration studies (in-
cluding lab-based studies). Published study protocols 
and conference abstracts, whose results were not yet re-
ported in a full paper, were also included to cover the 
latest advances in the use of accelerometers. 
(2) Patient population. Studies were eligible if they involved 
at least 10 adult HF patients; studies that involved mix of 
patients with various diagnoses were only included if 
they reported on the outcomes of HF patients sepa-
rately. Furthermore, studies were excluded if they in-
cluded patients with implanted left ventricular assist 
device or if they included patients on the basis of their 
self-diagnosis of HF (e.g. papers analysing the UK Biobank 
database). 
(3) Devices. Studies employing all types of wearable devices 
containing accelerometers (capacitive, piezoresistive, 
and piezoelectric) were eligible. However, studies using 
pedometers with a mechanical pendulum were excluded. 
In addition, studies that used accelerometers embedded 
in implantable devices (e.g. in resynchronization devices) 
were excluded. 
(4) PA metrics. To be eligible, studies had to report on at 
least one PA or sedentary behaviour metric. Studies that 
used accelerometers only as a tool for patients’ 
self-monitoring without reporting on PA metrics were ex-
cluded. Similarly, feasibility, usability, and other studies 
that used accelerometers but did not report on PA met-
rics were excluded. Finally, studies that employed accel-
erometers for other purposes than assessing PA and 
sedentary behaviour (e.g. sleep analysis and 
seismocardiography) were also excluded. 
Data extraction 
Data were extracted by three of the reviewers (T. V., M. B., 
and C. C.), using an Excel spreadsheet. Extracted information 
included study and population characteristics, details of 
accelerometry data collection and processing, and description 
of PA metrics. When a paper referred to supplementary mate-
rials and previously published papers (e.g. study protocols and 
pilot studies) for details, theses were retrieved and extracted. 
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Quality of reporting Study characteristics 
To assess the quality and completeness of accelerometer 
reporting, the papers were scored using 12 questions on ac-
celerometer information and data collection and processing 
(Table 1) as proposed by Montoye et al.9 Manuscripts were 
given a ‘+1’ score for adequately reported item and a ‘1’ 
score for not adequately reported item. The number of ‘1’ 
scores was summed, and each paper was, therefore, given 
a score of 0 to 12, with scores closer to 0 indicating more 
complete reporting. 
At several circumstances, some questions were not rele-
vant to the study, and the items were not assessed. Firstly, 
when the manufacturer only had one model of a specific 
brand (e.g. GeneActiv and RT3), the question about the accel-
erometer model was not assessed (Question 1). Secondly, 
study protocols were not scored for the question about the 
number of participants enrolled at study start (Question 5). 
Thirdly, the question about compliance with wear-time 
criteria was not assessed in studies that did not report any 
wear-time criteria (Question 12). Finally, validation studies 
that were conducted in a laboratory setting, under direct ob-
servation of researchers, were not assessed at all, as most of 
the questions would be irrelevant. 
Results 
The database search yielded 1226 articles; of those, 139 full 
texts were retrieved, and 59 deemed eligible.10-67,93 Hand 
searching the reference lists of recent reviews identified 
one additional eligible paper.68 Two of the papers used the 
same patient population but reported on two distinct studies; 
hence, they were both included.27,28 In total, 60 papers were 
included in the review, as shown in PRISMA flow diagram 
(Figure 1). Their full list and the data extracted from these pa-
pers are available as Data S2. 
Thirty-two papers reported on observational studies,10-
13,17,18,20,21,23-25,28,33,36,37,39-41,43,44,46,47,50,52,53,56,60,61,64-66,93 
12 on randomized controlled trials,14–16,22,32,45,49,55,62,63,67,68 
three on quasi-experimental studies,31,34,38 and eight on val-
idation studies (of those, four were supervised lab-based 
studies).27,29,30,35,42,48,54,58 Furthermore, five published study 
protocols were included.19,26,51,57,59 
The vast majority (n = 52) of the papers were published in 
the past 10 years (since 2010), and almost a half (n = 26) were 
published between January 2017 and September 2019. The 
greatest number of studies originated in the USA (n = 23), 
followed by the UK (n = 8), Germany (n = 7), and Japan 
(n = 4). 
Patient characteristics 
Patient characteristics are reported from 54 studies: study 
protocols19,26,51,57,59 are not included, and the two studies 
using the same population27,28 are only included once. Alto-
gether, 3500 HF patients participated in the reviewed studies; 
of those, 1088 in randomized controlled trials. 
Twenty studies included only HF with reduced ejection 
fraction (HFrEF) patients, three studies included only HF with 
preserved ejection fraction (HFpEF) patients, and nine studies 
included both HFrEF and HFpEF patients (but only two of 
them reported their characteristics separately). In summary, 
these studies included 1813 HFrEF patients and 536 HFpEF 
patients. The remaining 22 studies did not specify the form 
of HF. 
All but three studies reported participant sex; and 42 out 
of 51 studies recruited more men than women. Altogether, 
the studies included 1157 women and 2295 men. Thirty-one 
studies indicated the proportion of patients according to their 
functional New York Heart Association (NYHA) class: 10% of  
NYHA I, 50% of NYHA II, 38% of NYHA III, and 2% of NYHA 
IV patients were recruited. The descriptive statistics of other 






Brand of accelerometer used 55 2 
Model of accelerometer used 31 3 
Epoch length used 55 60 
Placement of accelerometer (must indicate location and side of the body) 55 64 
Number of participants enrolled at study start receiving accelerometers 51 0 
How were accelerometers distributed 55 0 
Days of data collected 55 4 
Criteria for defining non-wear of accelerometer 51 80 
How many minutes of accelerometer data needed to be considered a valid day 55 78 
Number of valid days of accelerometer data needed 55 76 
What were physical activity outcome variables 55 5 
Reported the number of people not meeting wear-time criteria 24 13 
aScore ‘1’ is undesirable. 
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FIGURE 1 PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram. 
reported patient characteristics, together with the number of 
reporting papers, are summarized in Table 2. 
Data collection 
In total, 27 accelerometer brands and 46 models were used in 
the reviewed studies. In addition, four studies used 
custom-made accelerometers, and two studies did not specify 
the brand. The most frequently used brand was Actigraph 
(n = 12); followed by Fitbit and RT3 (both n = 5); Actiwatch, 
Aipermon, Omron, and SenseWear (all n = 4); and GeneActiv 
(n = 3). 
The most common placement of the accelerometer was at 
the hip/waist/belt (n = 32), followed by wrist (n = 17), thigh 
(n = 7), chest (n = 7), and ankle (n = 3). In 11 cases, the place-
ment site was not reported. The accelerometers were equally 
placed on the right/dominant (n = 17) or left/non-dominant 
(n = 16) side. In two cases, the accelerometers were 
Table 2 Patient characteristics 
alternated between left and right sides. The side was not re-
ported in 42 cases. Note that the number of placement cases 
is higher than number of studies, as some studies used mul-
tiple accelerometers at different sites and/or sides. 
The wear protocol was either full 24 h (n = 23) or limited to 
waking hours (n = 16). In four validation studies, the acceler-
ometer was worn only for the purpose of a lab-based testing, 
and 17 studies did not report the wear protocol at all. The 
wear period ranged from 1 day to 1 year (median: 7 days, 
inter-quartile range: 4–9 days), and a 7-day wear period 
was the most frequent (n = 22). Three studies did not report 
the wear period at all. 
Data processing 
The length of epochs to which the accelerometer signal was 
aggregated was indicated in 23 studies. The epoch length 
Minimum Quartile 1 Median Quartile 3 Maximum Number of reporting papers (out of 54) 






















6MWD (m) 243 306 386 413 510 22 
PeakVO2 (mL/min/kg) 10 14 15 19 21 12 
BNP (ng/L) 148 164 190 263 379 7 
NT-proBNP (ng/L) 230 737 2027 2593 3727 6 
LVEF, left ventricular ejection fraction; 6MWD, 6-min walk distance. 
aHFrEF patients only. 
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varied from 1 s to  15 min, with 60 s being the most common 
epoch length (n = 13). 
The method for detecting non-wear time was described in 
10 studies; these included the algorithm of Troiano 2007 
(n = 2), another algorithm based on vector magnitude units 
(n = 2), a proprietary algorithm by Apple (n = 1), participants’ 
daily logs (n = 3), and impedance (n = 1) or heart rate (n = 1) 
sensors combined with the accelerometer in the form of a 
multi-sensor device. Specifically, of the 12 studies using an 
Actigraph, only three reported on the algorithm used to de-
tect non-wear time. 
The valid day definition, that is the minimum wear time re-
quired for a day to be included in the analysis, was indicated 
in 12 studies; it ranged from 480 to 1200 min (median: 
600 min). Among studies using an Actigraph, only four re-
ported the valid day definition. 
The minimum number of valid days required for a patient 
to be included in the analysis was reported by 13 studies. 
Of those, there were nine studies with a 7 day wear protocol, 
and these required 2 (n = 2), 3 (n = 3), 4 (n = 2), or 5 (n = 2) 
valid days. Of the 13 studies that reported the minimum 
number of valid days, only seven indicated the valid day def-
inition, and only three described how non-wear time was 
detected. 
Physical activity metrics 
The daily number of steps was the most often reported mea-
sure of PA (n = 20), followed by arbitrary activity ‘counts’ 
(n = 15), time spent in PA intensity levels (n = 14), energy ex-
penditure (n = 8), and time spent in various body postures 
and activities (n = 5). 
Of the 14 studies that reported on the time spent in differ-
ent intensities of PA, seven employed an Actigraph acceler-
ometer, and of these, four used Freedson 1998 cut points 
(in one case combined with Matthews 2005 cut points), one 
used Troiano 2008 cut points, and one did not state what 
cut points they used to distinguish between the PA levels. 
Three studies employed a SenseWear system, which uses 
multiple sensors (including accelerometers) to calculate in-
tensity levels on the basis of the proprietary algorithm. One 
study employing a GeneActiv accelerometer used a raw accel-
eration cut point (>100 mg) to calculate time spent in 
moderate-to-vigorous physical activity (MVPA). 
Other measures included performance during the most ac-
tive period of the day (e.g. most active 30 min), measures of 
variance (e.g. skewness and kurtosis) calculated from the 
most active periods, time accumulated in intensity bins of 
raw acceleration, and measures of rest–activity patterns. 
Quality of reporting 
The quality and completeness of reporting were assessed in 
55 studies (four lab-based validation studies27,29,30,54 and a 
study protocol19 with a negligible accelerometer role were 
not assessed). Studies were scored on 9 to 12 items (mean: 
10.9 items). The percentage of ‘1’ scores for each of the 
12 items is depicted in Table 1. 
No study achieved the highest score (0), and only three 
23,40,58studies achieved a score of 1. The median score 
was 4 (range 1 to 6). Scores of individual studies can 
be found in Data S3. 
Validation studies 
Eight validation studies were included in our review. Three 
studies used wearable accelerometers to examine concurrent 
validity of PA data from accelerometers embedded in cardiac 
implantable devices in free living.35,42,48 Two studies investi-
gated the validity of accelerometers to measure patients’ per-
formance during a 6-min walk test.27,30 
Three studies assessed the validity of a wearable acceler-
ometer to quantify PA during a structured supervised 
protocol.29,54,58 In one study, the patients were asked to per-
form several everyday activities (e.g. reading, dressing, and 
walking), and the output of a custom-made accelerometer 
was compared with visual analysis of simultaneously made 
video recordings.54 The two other studies assessed step accu-
racy of accelerometers by visual observation on the treadmill 
and during free walking at various speeds. They both found 
that at speeds slower than 3.0–3.6 km/h, the accuracy of 
the devices substantially deteriorates.29,58 
In addition, one of these studies evaluated the free-living 
validity of consumer-level activity monitors as measures of 
step count, with an Actigraph wGT3X-BT used as the crite-
rion. The study evaluated six devices (Fitbit Charge 2, Garmin 
vívofit and vívofit 3, Withings Go, Omron HJ-322U-E, 
SmartLAB walk+) and concluded that most of them perform 
to a reasonable enough standard to be useful tools that clini-
cians can use to motivate HF patients to walk more.58 
Discussion 
This systematic review is the first study to provide a compre-
hensive overview of the use of accelerometers in the assess-
ment of PA and sedentary behaviour in HF patients. Despite 
the fact that accelerometers are becoming more common-
place in the assessment of PA in HF patients, until the current 
review, there was no consensus to provide much needed 
guidance to clinicians and exercise scientists wishing to em-
ploy accelerometers in this population. 
In this review, we assessed 60 studies that used a wide va-
riety of accelerometer brands and models, with Actigraph be-
ing the most frequent (n = 12). The accelerometer was usually 
worn on the hip (n = 32), and the most prevalent wear period 
was 7 days (n = 22). The most common measures of PA were 
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steps (n = 20), activity counts (n = 15), and time spent in 
MVPA (n = 14). Only two studies used raw accelerometry 
data.16,32 No study used machine learning or other emerging 
analytical techniques.69 
Considering the quality of reporting, studies failed to re-
port between one and six (median 4) of the 12 items that 
were suggested as important for replication and correct inter-
pretation of results of accelerometer studies.9 The most 
underreported items included the criteria for defining 
non-wear time, minimum number of minutes needed to be 
considered a valid day, and number of valid days needed 
for a patient to be included in the analysis. 
Quality of reporting 
Two systematic reviews have recently evaluated the quality 
and completeness of reporting on data collection and pro-
cessing in general populations9 and cancer survivors.70 When 
comparing our results with the aforementioned reviews, cau-
tion must be taken, as the scoring has not been sufficiently 
standardized among the studies. 
Despite the non-standardized scoring procedures, many ob-
servations can be made. Notably, most studies in our review 
failed to report the details of data processing. Specifically, 
80% of the studies failed to report criteria for defining non-
wear, as compared with 69% in general populations9 and 
49% in cancer survivors.70 Furthermore, 78% of our studies 
did not report how many minutes of accelerometer data were 
needed to be considered as a valid day, and 76% failed to men-
tion the number of valid days needed for the inclusion of a pa-
tient in the analysis. These percentages are substantially worse 
than those reported in general populations (50% and 52%, 
respectively)9 and cancer survivors (38% and 43%, 
respectively).70 We are reluctant to use this anecdotal evi-
dence to claim that the quality of reporting in studies with 
HF patients is inferior to that in general populations or in can-
cer survivors. However, we are confident in asserting that 
reporting on data collection and especially processing 
methods needs to be markedly improved, as it is crucial for 
replicating and comparing future accelerometry-based 
studies. Thus, clinicians and researchers are strongly 
encouraged to report accelerometry studies in accordance 
with the checklist developed by Montoye et al.9 and 
presented in Table 1, or other best practices.71 
Physical activity metrics 
Although the majority of the studies were published in the 
past 10 years, most of them included traditional PA metrics 
such as steps, activity counts, and time spent in arbitrary PA 
intensities. When these metrics were first introduced, they 
simply reflected the capabilities of the technologies available 
at that time. Whilst these traditional metrics greatly contrib-
uted to the advancement of PA research, in particular the ob-
jectification of PA, they have several limitations that need to 
be considered.72 
Even though we excluded studies that used 
pendulum-based pedometers, step count was the most fre-
quently used measure of PA, reported in 33% of the studies. 
Because step count is intuitively understood by researchers, 
clinicians, and patients, it is useful for self-monitoring pur-
poses and as a basis for simple practical recommendations. 
However, it only accounts for locomotion (walking and run-
ning) and does not cover the whole spectrum of PA (swim-
ming and cycling). Furthermore, the step-counting 
algorithms provided by various manufacturers are all proprie-
tary and use different thresholds of acceleration to detect a 
step, which limits the comparability among studies using dif-
ferent devices.73 Despite numerous validation studies show-
ing that most commercially available accelerometers are 
more or less equal in general populations with normal 
gait,74,75 other studies have reported that step-counting ac-
curacy deteriorates in patients with chronic conditions, par-
ticularly during slower gait speeds.58,76 As such, steps can 
still remain a useful self-monitoring metric for patients but 
should be avoided by researchers striving for high accuracy 
and reproducibility of their findings. 
Along with step counts, activity counts were the second 
most common metric, reported in 25% of the studies. The 
common method to obtain activity counts includes using a 
proprietary integration algorithm to calculate the area under 
the curve of the accelerometer signal for a given time 
window.77 If steps were criticized for the proprietary charac-
ter of step-counting algorithms, activity counts are not only 
proprietary but also arbitrary in that they do not describe 
any specific construct of PA. Consequently, studies using dif-
ferent devices cannot be directly compared, and the use of 
activity counts should be discouraged. Albeit in normal popu-
lations, Rowlands et al. have robustly demonstrated the util-
ity of assessing the raw acceleration signal to gain inference 
into PA, where such an approach is free from user-selected 
arbitrary thresholds.78 
Time spent in PA intensity levels, particularly in MVPA, was 
reported in 23% of the studies. Time spent in MVPA is a stan-
dard measure of PA, which is related to the most current PA 
guidelines that recommend achieving at least 150 min of 
MVPA weekly.1 To calculate the time spent in MVPA, acceler-
ometer output needs to be calibrated, usually against indirect 
calorimetry, to establish cut points distinguishing between 
various intensity levels.79 However, different populations 
(e.g. children vs. adults vs. elderly) have drastically different 
cut points, whilst different placements (e.g. hip vs. wrist) and 
number of accelerometer axes (vertical axis vs. sum of all three 
axes) also produce different cut points.80,81 Hence, for each 
specific situation, there needs to be a calibration study produc-
ing specific cut points. Once this prerequisite is met, time 
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spent in MVPA can be directly compared among studies with 
different accelerometers, in theory. In reality, wearing the 
same accelerometer model concurrently at various place-
ments produces strikingly varying results (4–66 min of MVPA 
per day) even though the appropriate cut points are applied.81 
Furthermore, using cut points that were derived from normal 
healthy populations to calculate time spent in MVPA in pa-
tients with reduced cardiorespiratory fitness [e.g. HF, chronic 
obstructive pulmonary disease (COPD), and obese] is inher-
ently flawed. Unfortunately, to the best of our knowledge, 
no cut points specific for HF patients have been devised. 
Recently, it has been suggested that raw acceleration 
(Euclidean Norm minus 1 g, ENMO), rather than activity 
counts, could and should be used to develop PA intensity 
levels cut points.82 Even though this approach does not solve 
the above-mentioned calibration issue, it enables us to com-
pare studies that use different accelerometers, provided they 
produce raw acceleration output (Actigraph, GeneActiv, and 
Axivity).74 Unfortunately, this approach has been used only 
by one of the reviewed studies.16 
Regardless whether cut points are expressed in activity 
counts or raw acceleration, using time spent in PA intensity 
levels has other disadvantages.72 For example, many HF pa-
tients are likely to fail to obtain any activity above the MVPA 
cut point; consequently, a large number of study participants 
score 0 min, as was the case in one of the reviewed studies 
where median minutes of MVPA were zero.65 Rowlands 
et al. recently suggested several new metrics on the basis 
of raw acceleration, such as the level of acceleration above 
which a person’s most active 30 min are accumulated 
(M30),72 or intensity gradient, which can be used in combina-
tion with average acceleration to fully describe PA profile.83 A 
similar approach has been employed by one of the reviewed 
studies that calculated time accumulated in narrow intensity 
bins (0–20–40–60–80–100 mg) of raw acceleration.32 
Practical recommendations 
(1) Limit the use of steps only to the studies that focus on 
walking, for example, when the aim of the intervention 
is to increase daily number of steps, or when partici-
pants are instructed to self-monitor their steps.57 In ad-
dition, researchers and clinicians must be cognizant of 
the inaccuracy of most devices at slow gait speeds.58 
(2) Use time spent in PA intensity levels with caution, espe-
cially in patients with reduced cardiorespiratory fitness. 
Consider developing cut points on the basis of raw accel-
eration, specific for the population of interest or individ-
ually tailored cut points.79,84 
(3) Whenever possible, use accelerometers that provide raw 
acceleration output.78 Also, consider using recently de-
veloped metrics such as average acceleration, intensity 
gradient, or acceleration above which the most active 
30 min is accumulated.72,83 These can be easily calcu-
lated using a GGIR package in R.85 
(4) When choosing the accelerometer brand and model, any 
device featuring triaxial accelerometry and providing raw 
acceleration data is suitable. There are currently three 
major, research-grade brands on the market that comply 
with these requirements: Actigraph, Axivity, and 
GeneActiv. On the other hand, additional compliant de-
vices are likely available.74 
(5) With regard to the data collection and processing, there 
are no validation/calibration studies or studies compar-
ing different protocols specifically in cardiovascular pa-
tients; therefore, we can only mirror the 
recommendations that were devised for general 
populations86 and other chronic conditions, such as 
COPD.87 As such, these recommendations need to be 
considered as merely a starting point for the specific 
choices that will always reflect the study aims and the 
previously selected PA metrics. 
Wear time 
Most researchers agree on 24 h wear for seven continuous 
days. As opposed to waking-hours-only protocols, 24 h data 
cover all physical behaviours (including sleep) and enable 
the analysis of their interplay using techniques such as com-
positional analysis or isotemporal substitution. However, 
when a study only focuses on MVPA or daily step count, 
there is no need for 24 h wear, and waking-hours-only proto-
cols should suffice. 
Placement 
There is no consensus regarding device placement. 
Wrist-worn accelerometers seem to have a slight edge, 
mostly because they achieve the best compliance with 24 h 
wear88 and because the most widespread open-source tool 
for analysing raw data (GGIR package in R) was originally de-
veloped for wrist-worn data.85 However, the traditional 
hip/waist placement is still preferred by many researchers, 
as it seems to have better validity for some physical 
behaviours.82,89 When the study focus is on sedentary behav-
iour, thigh placement is currently considered the gold 
standard.90 In populations with decreased functional capac-
ity, ankle placement is also gaining popularity as it performs 
well even with slow gait where other placements usually 
fail.79,91 In a review by Clark et al., the authors advocated that 
there is no ‘one site fits all’ approach to the selection of accel-
erometer site or analytical technique, and that study design 
and focus should always inform the most suitable location 
of attachment, and be driven by the type of activity being 
characterized.92 
Processing methods 
The first step in data processing that requires some decision 
making is the detection of non-wear time. The algorithms 
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used for non-wear detection are usually embedded in the 
software used for accelerometer data analysis. For example, 
the open-source GGIR package estimates non-wear time on 
the basis of the standard deviation and the value range of 
the raw data from each accelerometer axis.85 Actilife, the 
proprietary software developed by the manufacturer of 
Actigraph devices, enables a choice between several algo-
rithms on the basis of Actigraph-specific activity counts. In 
the absence of an algorithm specific for HF patients, we ten-
tatively recommend using the Choi algorithm, which is con-
sidered to be the best performing in older adults.86 
Following non-wear detection, a decision of how many mi-
nutes of wear time is required for a day to be valid needs 
to be made; the general consensus is 600 min (10 h).86 Alter-
natively, the GGIR package replaces the non-wear sections by 
imputed values calculated as an average of the same time 
point on all other days of the measurement.85 Finally, for a 
patient to be included in the analysis, at least four valid days, 
including at least one weekend day, is usually required.86 
Conclusions 
In our systematic review of 60 studies using accelerometers 
in HF patients, we demonstrated large heterogeneity and a 
lack of consensus in the methods used for accelerometer 
data collection, handling, and processing. Furthermore, we 
found that despite well-founded limitations, traditional met-
rics such as steps, activity counts, and time spent in PA inten-
sity levels still prevail, revealing an opportunistic gap in the 
use of metrics based on raw acceleration and machine learn-
ing techniques. Finally, we encourage researchers and clini-
cians to improve the quality and transparency of reporting 
on data collection and processing by following our proposed 
practical recommendations for the use of accelerometers in 
patients with cardiovascular diseases. 
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